Cooper/Haims Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $600K | Buy |
2,761
+43
| +2% | +$9.54K | 0.28% | 40 |
|
|
2025
Q4 | $621K | Sell |
2,718
-216
| -7% | -$49.2K | 0.28% | 40 |
|
|
2025
Q3 | $679K | Sell |
2,934
-86
| -3% | -$17.5K | 0.32% | 35 |
|
|
2025
Q2 | $560K | Buy |
3,020
+86
| +3% | +$16K | 0.28% | 36 |
|
|
2025
Q1 | $615K | Sell |
2,934
-26
| -0.9% | -$5.05K | 0.33% | 31 |
|
|
2024
Q4 | $526K | Hold |
2,960
| – | – | 0.3% | 36 |
|
|
2024
Q3 | $584K | Hold |
2,960
| – | – | 0.32% | 35 |
|
|
2024
Q2 | $508K | Sell |
2,960
-394
| -12% | -$65.3K | 0.28% | 40 |
|
|
2024
Q1 | $611K | Sell |
3,354
-12
| -0.4% | -$2.07K | 0.36% | 30 |
|
|
2023
Q4 | $522K | Sell |
3,366
-497
| -13% | -$72.5K | 0.3% | 31 |
|
|
2023
Q3 | $576K | Sell |
3,863
-19
| -0.5% | -$2.79K | 0.45% | 27 |
|
|
2023
Q2 | $523K | Buy |
3,882
+23
| +0.6% | +$3.37K | 0.4% | 32 |
|
|
2023
Q1 | $615K | Sell |
3,859
-125
| -3% | -$19.1K | 0.49% | 29 |
|
|
2022
Q4 | $644K | Sell |
3,984
-281
| -7% | -$43.1K | 0.46% | 28 |
|
|
2022
Q3 | $572K | Buy |
4,265
+2
| +0% | +$287 | 0.47% | 30 |
|
|
2022
Q2 | $653K | Buy |
4,263
+126
| +3% | +$19.3K | 0.43% | 26 |
|
|
2022
Q1 | $671K | Sell |
4,137
-1,199
| -22% | -$174K | 0.44% | 31 |
|
|
2021
Q4 | $722K | Hold |
5,336
| – | – | 0.44% | 31 |
|
|
2021
Q3 | $576K | Hold |
5,336
| – | – | 0.35% | 35 |
|
|
2021
Q2 | $601K | Hold |
5,336
| – | – | 0.39% | 32 |
|
|
2021
Q1 | $577K | Hold |
5,336
| – | – | 0.41% | 29 |
|
|
2020
Q4 | $572K | Hold |
5,336
| – | – | 0.44% | 25 |
|
|
2020
Q3 | $467K | Buy |
5,336
+1
| +0% | +$94 | 0.38% | 26 |
|
|
2020
Q2 | $524K | Buy |
5,335
+17
| +0.3% | +$1.5K | 0.43% | 24 |
|
|
2020
Q1 | $405K | Hold |
5,318
| – | – | 0.35% | 25 |
|
|
2019
Q4 | $471K | Buy |
5,318
+500
| +10% | +$41.5K | 0.26% | 26 |
|
|
2019
Q3 | $365K | Hold |
4,818
| – | – | 0.22% | 31 |
|
|
2019
Q2 | $350K | Sell |
4,818
-1,000
| -17% | -$78.6K | 0.22% | 33 |
|
|
2019
Q1 | $469K | Hold |
5,818
| – | – | 0.3% | 23 |
|
|
2018
Q4 | $536K | Sell |
5,818
-481
| -8% | -$42.3K | 0.37% | 21 |
|
|
2018
Q3 | $596K | Hold |
6,299
| – | – | 0.41% | 18 |
|
|
2018
Q2 | $584K | Buy |
6,299
+1,004
| +19% | +$98.1K | 0.43% | 17 |
|
|
2018
Q1 | $501K | Hold |
5,295
| – | – | 0.44% | 18 |
|
|
2017
Q4 | $512K | Buy |
+5,295
| New | +$499K | 0.47% | 17 |
|
Other funds holding ABBV
VCM
VPM
Cooper/Haims Advisors's ABBV Position: Q1 2026 in Review
Cooper/Haims Advisors increased its AbbVie (ABBV) stake by 1.6% in Q1 2026, buying an estimated $9.54K and bringing the position to 2,761 shares worth $600K. The position accounts for 0.28% of the portfolio, ranked #40.
Cooper/Haims Advisors first reported a position in ABBV in Q4 2017 and has held it in 34 quarters since. The position peaked at $722K in Q4 2021. 4,079 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Cooper/Haims Advisors held 2,761 shares of AbbVie worth $600K as of Q1 2026.
- Cooper/Haims Advisors bought 43 AbbVie shares in Q1 2026, an estimated $9.54K.
- AbbVie made up 0.28% of Cooper/Haims Advisors's portfolio in Q1 2026, its #40 holding.
- Cooper/Haims Advisors first reported a position in AbbVie in Q4 2017 and has held it in 34 quarters since.
- Cooper/Haims Advisors's AbbVie position peaked at $722K in Q4 2021.
- 4,079 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Cooper/Haims Advisors's 13F filing for Q1 2026, filed 12 May 2026.